Up-regulation of activating and inhibitory NKG2 receptors in allogeneic and autologous hematopoietic stem cell grafts

Table 1 Allotransplanted patients

Patient	Age	Diagnosis^a	Donor^b	Source of graft^c	Conditioning regimen^d	aGvHD^e stage	Onset of aGvHD (days)	Relapse (days)	Last follow up (days)	Status at last follow up	Cause of death
149	32	AML	U	PB	MAC	No	-	69	156	Dead	Relapse/Progression
150	26	DLBCL	R	PB	RIC	I	38	no	149	Dead	Infection
151	49	AML	R	PB	MAC	IV	12	124	293	Dead	Fungal Infection - Rejection/Poor graft Function^f
152	33	B-ALL^g	U	PB	MAC	III	88	no	137	Dead	Infection
153	37	SAA	R	PB + BM	MAC	II	40	no	307	Dead	Unknown
154	46	AML^h	R	PB	MAC	No	-	299	365	Dead	Haemorrhage - CNS Toxicity
155	42	MM	R	PB	MAC	No	-	151	485	Dead	Relapse/Progression

^aAML, acute myeloid leukemia; DLBCL, Diffuse Large B cell Lymphoma; B-ALL, B-cell Acute Lymphoid Leukemia; SAA, Severe Aplastic Anemia; MM, Multiple Myeloma
^bMatched related (R) and matched unrelated (U) donor
^cPB, peripheral blood; BM, bone marrow
^dMAC, MyeloAblative Conditioning regimen; RIC, Reduced Intensity Conditioning
^eaGvHD, acute Graft versus Host Disease
^fremission induced by chemotherapy upon relapse (day 124)
^gPatient previously diagnosed (year 1991) with CML t(9;22)
^hSubclass III, according to the French American British classification of AML

ISSN: 1756-9966